Millenium Pharma .... markiert den Kalender "rot" !!!!

[Ralph]

Am 13./14.12.00 kommt das ODAC zusammen ! .... nein, nicht der Automobil-Club des Oman http://www.stock-channel.net/Board/smilies/newlaugh.gif

.... sondern das "Oncologic Drugs Advisory Committee" <IMG SRC="http://www.stock-channel.net/Board/icons/icon18.gif" border=0>

.... toll, was hat dies mit MLNM zu tun - sehr viel !

Die ODAC ist ein Gremium, das Medikamente unter die Lupe nimmt ! .... genaugenommen wird dies "Campath" von Millenium/ILXO und "Maxamine" von Maxim sein !

Unter Analysten gilt die ODAC als eines der schwierigsten Gremien überhaupt ! .... der Tag könnte echt denkwürdig werden ! .... mal sehen, wie ich den "spiele" .... vielleicht 'nen "Straddle" ! http://www.stock-channel.net/Board/smilies/smile.gif

Ralph

[Büffel]

MLNM hat mir heute wieder schöne $$$ reingesprudelt.

wurde auch zeit.http://www.stock-channel.net/Board/smilies/biggrin.gif

mal sehen,bei meinem 40euro einstieg werde ich dann nächste
woche doch erstmal gewinne mitnehmen.http://www.stock-channel.net/Board/smilies/smile.gif
schaun mer mal,wie die kommende woche verläuft.

was ma hat das hat mahttp://www.stock-channel.net/Board/smilies/biggrin.gif

büffel

[Dieser Beitrag wurde von Büffel am 25.11.2000 editiert.]

[Trüffelschwein]

Robertson Stephens Daily Growth Stock Update on AMTD NITE CALP CELG EGRP EXDS DNA IBAS MLNM SONE

SAN FRANCISCO, Dec. 4 /PRNewswire/ -- The following is being issued by Robertson Stephens, a member of the National Association of Securities Dealers, CRD number 41271:

....

"Millennium Pharmaceuticals hosted a symposium entitled "CAMPATH-1H - an emerging therapy" on Friday, December 1, at the American Society of Hematology (ASH) in San Francisco," said King. "CAMPATH-1H is a chimeric humanized antibody to the CD52 antigen on lymphocytes and monocytes. CAMPATH is a drug candidate for the treatment of chronic lymphocytic leukemia (CLL). Dr. Keating presented results from a Phase II study of refractory patients, demonstrating an overall intent-to-treat response rate of 33% (n=93) with two complete responses, 29 partial responses and 55 stable diseases. CAMPATH is scheduled to be reviewed by ODAC on December 14. We are anticipating a positive review with FDA approval shortly thereafter, and believe the clinical picture of the drug is emerging more clearly. While important as the company's first product, we believe Millennium has one of the richest pipelines in the industry focused on oncology, metabolism and inflammation. Millennium currently has six products in the clinic with the potential for another four yet to come this year. We reiterate our Strong Buy rating on Millennium Pharmaceuticals."

....

[Trüffelschwein]

Noch mehr Balsam für MLNM-Fans wie mich:


Millennium's LDP(PS)-341 Inhibits Growth and Induces Death of Cancer Cells, Appears to Overcome Chemotherapy Resistance

SAN FRANCISCO, Dec. 4 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the presentation of preclinical and clinical study results demonstrating that an investigational proteasome inhibitor, LDP- 341 (formerly PS-341), the first in a new class of anti-cancer agents, is active against multiple myeloma. The latest findings were presented at the 42nd Annual Meeting of the American Society of Hematology (ASH) meeting in San Francisco. ( Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The first presentation, entitled "The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis and Overcomes Drug Resistance in Human Multiple Myeloma (MM) Cells," was based on research conducted by Teru Hideshima, Ph.D, M.D., and colleagues at Dana-Farber Cancer Institute and Harvard Medical School in collaboration with Millennium. In the preclinical study, LDP-341, a proprietary small molecule compound, showed in vitro activity against multiple myeloma cells, resulting in the inhibition of cancer cell growth and reproduction, and the inducement of cell suicide (apoptosis), in animals. The potent anti-tumor action of LDP-341 on multiple myeloma cells in these preclinical studies appears to involve both direct (apoptosis) and indirect inhibition of growth factors which promote tumor growth. In addition, in animals LDP-341 appears to increase the effectiveness of other anti-cancer drugs by overcoming cellular resistance, which in humans is a major cause of chemotherapy failure.

Clinical research was presented at the meeting by Thomas Stinchcombe, M.D., and principal investigator Robert Orlowski, M.D., Ph.D., in a report entitled "PS-341 is Active in Multiple Myeloma: Preliminary Report of a Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Hematologic Malignancies." Drs. Stinchcombe and Orlowski are affiliated with the University of North Carolina at Chapel Hill and performed the research in collaboration with colleagues and Millennium. The study presents data from a recent Phase I clinical trial. In the study of nine heavily pretreated patients with advance hematological malignancies, three patients with multiple myeloma were treated with LDP-341 over a four-out-of-six week cycle. LDP-341 reduced serum myeloma protein levels and myeloma cell numbers in bone marrow in two of these three patients with advanced multiple myeloma. The drug was well-tolerated by these patients and in addition appears to have induced a complete response in one patient and a reduction in bone marrow plasma cells in another.

"The results are encouraging because clinically significant responses are rare in advanced stage, heavily pretreated patients. Preliminary findings support more advanced clinical studies to explore LDP-341's use in refractory treatment for multiple myeloma and other blood-borne cancers," said Dr. Orlowski.

According to Julian Adams, Ph.D., senior vice president, research and development at Millennium, LDP-341's novel mechanism of action and its role in the metabolism of a variety of proteins with critical cell function make it a promising candidate for the treatment of cancer. "Proteasome inhibition is a prime strategy for developing new therapeutic agents to combat solid tumor and hematologic cancers, including multiple myeloma," said Dr. Adams. "Based on our findings, we will further explore the safety and efficacy of LDP-341 in numerous clinical trials as both a single agent and in combination with other chemotherapeutic agents. Millennium is committed to initiating additional studies in multiple myeloma in the coming months."

In addition to the studies discussed at the ASH meeting, the National Cancer Institute is conducting an extensive program of LDP-341 clinical trials under a Cooperative Research and Development Agreement with Millennium. A number of Phase I trials of LDP-341 in combination with other chemotherapeutic agents are planned as well as Phase II studies. The first combination study, LDP-341 with 5-FU and leucovorin, was initiated at the University of Southern California Norris Comprehensive Cancer Center, directed by principal investigator Heinz-Josef Lenz, M.D.

"Through its oncology franchise, Millennium is committed to developing safer, more effective cancer therapies," said Lee Brettman, M.D., senior vice president, clinical development and medical affairs, Millennium. According to Brettman, Millennium will examine the pharmacogenomic information derived from clinical studies with LDP-341 in the hopes of revealing the genetic controls for cancer cell responsivity or resistance to therapy. "Millennium may then use this data to develop Diagnomic(TM) and pharmacogenomic tests to predict which patients will most likely respond to specific therapies," Dr. Brettman explained. Multiple Myeloma

Multiple myeloma is a type of cancer characterized by the excessive growth of the immune system's plasma cells. More than 36,000 Americans have multiple myeloma and about 13,000 develop the cancer each year, according to the NCI. The disease is difficult to cure- the disease is associated with a 28 percent five-year survival rate and a three percent ten-year survival rate (source: the Leukemia and Lymphoma Society and the National Cancer Institute).

Multiple myeloma occurs when the immune system's plasma cells undergo abnormal uncontrolled growth and reproduction. Multiple myeloma cells prevent the marrow from forming normal plasma cells and other white blood cells important to the immune system. Patients with multiple myeloma may not be able to fight infection and disease and often have anemia, bone pain or fractures and numbness or weakness of limbs.

Many multiple myeloma patients pursue chemotherapy treatment to improve the quality of life by controlling symptoms and limiting disease complications. Multiple myeloma usually is treated by a combination of drug therapies, but some patients may receive radiation therapy, bone marrow transplants or surgery. Proteasome Inhibition

In normal cells, the ubiquitin-proteasome pathway is responsible for the orderly breakdown of multiple proteins and thereby helps to define protein turnover rates. Proteasomes, large complexes of proteolytic enzymes, break down these intracellular proteins, recognizing them by their ubiquitin molecular tags. In addition to degrading unwanted proteins, the proteasome is involved in the generation of antigens and the regulation of cellular signals that govern growth and differentiation. In addition, proteasomes help generate antigens, which stimulate the production of antibodies.

Selective inhibition of proteasome activity has numerous effects, including attenuating the activity of NF-kB, the transcription factor that controls cellular inflammatory response. In tumor cells, proteasome inhibition produces overwhelming cellular stress by stabilizing cell cycle regulatory proteins and disrupting cell proliferation, ultimately leading to apoptosis. Millennium's Oncology Franchise

Millennium's approach to personalized medicine is demonstrated through the development of a portfolio of breakthrough products comprised of both therapeutic (both small molecule and antibody) and predictive programs. Inflammation, oncology and metabolic disease comprise Millennium's three key research and development franchise areas. In addition to LDP-341, the Company has a number of oncology-based targets and compounds in various stages of development that span from discovery research to advanced clinical trials. These programs include the CAMPATH(R) monoclonal antibody, a therapeutic owned by a joint venture of Millennium that is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia, the most prevalent adult form of leukemia. A Millennium alliance partne

[reg]

[Silke]

hi Ihr zwo,

habs mir auch mal mit Millennium überlegt. Und zwar in Form eines OS mit wenigKapitaleinsatz. Entweder hopp oder Topp http://www.stock-channel.net/Board/smilies/smile.gif

Hier die 710453 von der Commerzbank. Omega von über 3 das funkt dann recht ordentlich!

good luck
MM

[Trüffelschwein]

The European Biotech Report

Cancer drug 21-year odyssey at end?
From Cambridge University to a suburban Holiday Inn

By Jesse Schulman, FTMarketWatch 4:04:00 PM GMT Dec 8, 2000

LONDON (FTMW) -- After a 21-year odyssey through the academic and corporate wilderness, a potentially life-saving drug from a Cambridge University lab has its day of judgment next week before a committee of the U.S. Federal Drug Administration.
The drug is called Campath, which is short for "Cambridge Pathology", the university department in which it was first created by Dr. Herman Waldmann and his colleagues.

"My colleagues and I have always believed in it," Professor Waldmann told FTMarketWatch.com

A committee of specialists called the Oncologic Drugs Advisory Committee will meet on December 14 in the improbably-named Versailles Ballroom of a Holiday Inn near Washington D.C. to give Campath the thumbs-up -- or down -- as a treatment for a form of leukemia.

The FDA almost always follows the recommendations of its advisory committees. Approval could mean sales running into hundreds of millions of pounds annually, and give physicians an important new weapon against cancer.

Campath's developers say it also shows promise as a treatment for other types of cancer, for fighting rejection of transplanted organs, in multiple sclerosis and in aiding bone marrow transplantation.
Woeful tale

How Campath got from a lab in the Fens of Cambridgeshire, England to a suburban Maryland Holiday Inn ballroom is a long and sometimes woeful saga.

While he doesn't want to predict the outcome of the FDA's deliberations Waldmann says, "Campath succeeded because people believed in it, and because of old friendships."

The first version of Campath was produced in the Department of Pathology at Cambridge University, and the early work research and development work was done in academic institutions. The University of Cambridge and the Medical Research Council licensed Campath to BTG [UK:BGC], the U.K. technology investment company, which in turn licensed it to Wellcome Plc, later part of Glaxo Wellcome [UK:GLXO] [US:GLX].

But after encouraging preliminary trials, Wellcome dropped it, and it languished for years. Antibody-based drugs like Campath fell badly out of favour in the pharmaceutical industry in the 1990s.

Fall from grace

Those were discouraging times.

"It's harder for big pharmaceutical companies to take chances," Waldmann says. "The psychology is of people not wanting to stand out against the decisions of higher management.

"They're too worried about their careers, about not making a mistake," he adds.

Antibodies' fall from grace can seem hard to understand in retrospect, with antibody drugs like Genetech's [UShttp://www.stock-channel.net/Board/smilies/biggrin.gifNA] Herceptin, IDEC's [US:IDPH] Rituxan and others now each racking up sales in the hundreds of millions of pounds annually.

In addition, entire companies are now devoted to finding new antibody-based drugs, based on technology developed in Cambridge 25 years ago. See Antibody 'gold mine' feted in London

It was due to Waldmann's friendship with a scientist named Tim Springer, now at Harvard, that U.S. company LeukoSite decided Campath was a potential winner, and took a license to develop it.

"Small biotech companies are better able to take a chance, and it took LeukoSite to take Campath forward," Waldmann says.

The other Cambridge

LeukoSite was bought in 1999 by Millennium Pharmaceuticals [US:MLNM], based in "The Other Cambridge" (the one in Massachusetts). Millennium, in a 50:50 partnership with ILEX Oncology [US:ILXO], has now submitted the drug for U.S. marketing approval to treat a form of leukemia. Schering AG [UK:SCG] [DE:717200] and its U.S. subsidiary Berlex have distribution rights.

Campath has been a labour of love for a talented and devoted group of scientists, now spread out around the world. For a sense of their passion (and the scientific details), see Mike's Campath Story, written by one of the many scientists involved.

Campath could prove to be a commercial boon to the companies commercialising it, as well as to the University of Cambridge and to some of its inventors.

Waldmann is not, by the way, among those who stand to profit. He gave up his commercial rights long ago, and admits the saga has left its bruises.

"We have all become much more reflective. You can be too optimistic, and too pessimistic. My excitement is in knowing that physicians will be creative in getting the best out of Campath."

"I see it as a beginning," Waldmann said.

Jesse Schulman is biotechnology correspondent for FTMarketWatch.com in London. He owns shares in Millennium Pharmaceuticals.

Original-Link: http://www.ftmarketwatch.com/news/story.asp?guid={1FA6FE16-94C9-4E02-91DD-DD33028C2A83}

Mehr zu Campath unter: http://www.path.cam.ac.uk/~mrc7/campath/campath.html


MLNM wird zum 18.12.in den NASDAQ-100 aufgenommen und ist deshalb zuletzt stark gestiegen. Im Zusammenhang mit der Entscheidung über die Zulassung von Campath wäre für Trader vielleicht ein kleiner Zock drin...

Ciao, T.

[Eric]

US-Biotech – Millennium Pharma explodiert

Die Aktien des Pharmakonzerns Millennium Pharma [Nasdaq: MLNM] steigen am Donnerstag bis 18:20 Uhr (MEZ) um 10,9 Prozent auf 61,62 Dollar – und damit auf ein neues Rekordhoch.

Anleger reagieren mit ihren Käufen auf die Nachricht, dass ein Komitee der US-Aufsichtsbehörde FDA (Food and Drug Administration) dem Unternehmen für das experimentelle Krebsmedikament Campath seine Unterstützung zugesagt hat. Millenium hat das Medikament gemeinsam mit ILEX Oncology [Nasdaq: ILXO] entwickelt.

Das Medikament wäre für beide Firmen das erste Produkt im Markt. Zuvor muss allerdings noch die FDA Campath ihren Segen erteilen. Normalerweise folgt die Behörde aber den Empfehlungen ihrer Ausschüsse.

Das Komitee hatte sich mit 14 zu 1 Stimmen für Campath ausgesprochen.


© 14.12.20000 www.stock-world.de (http://www.stock-world.de)

[artistin]

Wow, ich weiß, wer sich gerade ganz doll freut.... http://www.stock-channel.net/Board/smilies/biggrin.gif http://www.stock-channel.net/Board/smilies/biggrin.gif http://www.stock-channel.net/Board/smilies/biggrin.gif http://www.stock-channel.net/Board/smilies/biggrin.gif Freu mich mit!!!

grüsse
artistin http://www.stock-channel.net/Board/smilies/smile.gif

[Trüffelschwein]

http://www.stock-channel.net/Board/smilies/biglaugh.gifhttp://www.stock-channel.net/Board/smilies/biglaugh.gifhttp://www.stock-channel.net/Board/smilies/biglaugh.gifhttp://www.stock-channel.net/Board/smilies/biglaugh.gif

Bei dem Marktumfeld muß man mit +8,09% wohl zufrieden sein.

@artistin:
Danke für Dein Mitfreuen!http://www.stock-channel.net/Board/smilies/smile.gifhttp://www.stock-channel.net/Board/smilies/smile.gif

Ciao, T.

[Eric]

Ich Freu mich auch vor allem auf die heutige kaufpanik http://www.stock-channel.net/Board/smilies/biglaugh.gif
http://www.stock-channel.net/Board/smilies/biglaugh.gif

Gruß Eric

[Joerg]

Es soll ja Zeiten geben, da macht Börse Spaß! Schaut Euch mal die Lieblingsaktie von vielen Boardlern an:

<IMG SRC="http://buerger.metropolis.de/stocksurfer/charts/amerika/bio/mlnm_151200.gif" border=0>

MLNM hat gestern vorbildlich an der GD-10 Halt gemacht und gedreht. Ich könnte mir ein weiters Up bis zum nächsten Widerstand vorstellen, der liegt bei ca 78$. Vor allem stimmt mich der hohe Umsatz, bzw. das hohe Volumen sehr positiv. Ein Blick auf die DMIs sieht auch positiv aus.
Da wir den Tag aber nicht vor dem Abend loben wollen, überlegen wir mal, bis wohin sie zurüchgehen könnte:

a) bis 65$, da liegt die GD-50
b) bis 61$, da liegt die erste Unterstützung

Good luck girls and boys
Joerg

[Büffel]

ich bin froh das ich noch kein stück
verkauft habe.
kk 40

büffel

[Joerg]

Oh je,
es ist schrecklich, man mag es ja schon wieder gar nicht aussprechen und vielleicht wird es ja auch anders kommen, aber die heutige Candleformation war ein negatives harami. Ein leichtes Verkaufssignal am Ende einer Aufwärtsbewegung ... Dies läßt erstmal wieder tiefere Kurse sehen, frage mich nur, ob da nicht andere Daten dieser klaren Interpretation zuvorkommen.

Abend und Nachtgruß
Joerg

[Ralph]

Joerg,

es war letzte Woche schon erkennbar, dass sich MLNM in einer Flagge bewegt (=Konsolidierung im intakten Abwärtstrend) ... niedrigere Kurse sind m.E. vorprogrammiert !

Ralph